» Articles » PMID: 32397705

Development of a Conformational Histamine H Receptor Biosensor for the Synchronous Screening of Agonists and Inverse Agonists

Overview
Journal ACS Sens
Specialty Biotechnology
Date 2020 May 14
PMID 32397705
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The histamine H receptor (HR) represents a highly attractive drug target for the treatment of various central nervous system disorders, but the discovery of novel HR targeting compounds relies on the assessment of highly amplified intracellular signaling events that do not only reflect HR modulation and carry the risk of high false-positive and -negative screening rates. To address these limitations, we designed an intramolecular HR biosensor based on the principle of bioluminescence resonance energy transfer (BRET) that reports the receptor's real-time conformational dynamics and provides an advanced tool to screen for both HR agonists and inverse agonists in a live cell screening-compatible assay format. This conformational G-protein-coupled receptor (GPCR) sensor allowed us to characterize the pharmacological properties of known and new H receptor ligands with unprecedented accuracy. Interestingly, we found that one newly developed H receptor ligand possesses even stronger inverse agonistic activity than reference HR inverse agonists including the current gold standard pitolisant. Taken together, we describe here the design and validation of the first screening-compatible HR conformational biosensor that will aid in the discovery of novel HR ligands and can be employed to gain deeper insights into the (in-)activation mechanism of this highly attractive drug target.

Citing Articles

Histamine H Receptor Isoforms: Insights from Alternative Splicing to Functional Complexity.

Gao M, Ooms J, Leurs R, Vischer H Biomolecules. 2024; 14(7).

PMID: 39062475 PMC: 11274711. DOI: 10.3390/biom14070761.


Computational drug development for membrane protein targets.

Li H, Sun X, Cui W, Xu M, Dong J, Ekundayo B Nat Biotechnol. 2024; 42(2):229-242.

PMID: 38361054 DOI: 10.1038/s41587-023-01987-2.


Discovery of a Tritiated Radioligand with High Affinity and Selectivity for the Histamine H Receptor.

Monnich D, Nagl M, Forster L, Rosier N, Igel P, Pockes S ACS Med Chem Lett. 2023; 14(11):1589-1595.

PMID: 37974943 PMC: 10641923. DOI: 10.1021/acsmedchemlett.3c00413.


Development of Fluorescent AF64394 Analogues Enables Real-Time Binding Studies for the Orphan Class A GPCR GPR3.

Bresinsky M, Shahraki A, Kolb P, Pockes S, Schihada H J Med Chem. 2023; 66(21):15025-15041.

PMID: 37907069 PMC: 10641823. DOI: 10.1021/acs.jmedchem.3c01707.


Pathway selectivity in Frizzleds is achieved by conserved micro-switches defining pathway-determining, active conformations.

Gratz L, Kowalski-Jahn M, Scharf M, Kozielewicz P, Jahn M, Bous J Nat Commun. 2023; 14(1):4573.

PMID: 37516754 PMC: 10387068. DOI: 10.1038/s41467-023-40213-0.


References
1.
Lazewska D, Kiec-Kononowicz K . Progress in the development of histamine H receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat. 2018; 28(3):175-196. DOI: 10.1080/13543776.2018.1424135. View

2.
Rapanelli M, Frick L, Pogorelov V, Ohtsu H, Bito H, Pittenger C . Histamine H3R receptor activation in the dorsal striatum triggers stereotypies in a mouse model of tic disorders. Transl Psychiatry. 2017; 7(1):e1013. PMC: 5545743. DOI: 10.1038/tp.2016.290. View

3.
Lutsenko K, Hagenow S, Affini A, Reiner D, Stark H . Rasagiline derivatives combined with histamine H receptor properties. Bioorg Med Chem Lett. 2019; 29(19):126612. DOI: 10.1016/j.bmcl.2019.08.016. View

4.
Liu J, Horst R, Katritch V, Stevens R, Wuthrich K . Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science. 2012; 335(6072):1106-10. PMC: 3292700. DOI: 10.1126/science.1215802. View

5.
Lim H, van Rijn R, Ling P, Bakker R, Thurmond R, Leurs R . Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther. 2005; 314(3):1310-21. DOI: 10.1124/jpet.105.087965. View